Data as of Nov 4, 2026.
PCOV vs TCAL: Dividend Yield & Total Return
PCOV and TCAL both write options for income.
askIQ about this page
askIQ about PCOV and TCALNet assets: $10m on Nov 2, 2026 for Principal Equity Premium Income ETF, and $324m on Nov 3, 2026 for T. Rowe Price Capital Appreciation Premium Income ETF.
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
Total return, distributions reinvested
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
1.9% of it arrived as cash. Total return, distributions reinvested. PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
Data to Nov 4, 2026.3.4 pts behind its own stocks
TCAL over 1 year: paid 11.4%, price −1.2%, total +11.2%, its own stocks +14.6%, −3.4 pts. Data to Nov 4, 2026.
its own stocks
+14.6%
TCAL
+11.2%
11.4% of it arrived as cash
3.4 pts behind its own stocks
Total return, distributions reinvested
3.4 pts behind its own stocks
TCAL over 1 year: paid 11.4%, price −1.2%, total +11.2%, its own stocks +14.6%, −3.4 pts. Data to Nov 4, 2026.
its own stocks
+14.6%
TCAL
+11.2%
11.4% as cash
11.4% of it arrived as cash. Both charts share one scale, with zero at the line. TCAL over 1 year: paid 11.4%, price −1.2%, total +11.2%, its own stocks +14.6%, −3.4 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
Both cost 0.34% a year; TCAL is far larger, $324m against $10m.
Points (pts) are percentage points.
| Measure | PCOV | TCAL |
|---|---|---|
| Paid and earned | ||
| Total return, 1 year | not published | +11.2% |
| Price change | fell 2.0% (since Aug 19, 2026) | fell 1.2% (1 year) |
| Against its benchmark | ||
| Benchmark | not published | its own stocks |
| Cost and size | ||
| Expense ratio | 0.34% | 0.34% |
| Net assets, as of Nov 3, 2026 | $10m | $324m |
| Holdings | ||
| Holdings in common | not published | |
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | PCOV | TCAL | PCOV | TCAL | PCOV | TCAL |
| 3 months | – | +5.3% | – | 2.6% | – | −1.8 pts |
| 6 months | – | +12.3% | – | 6.3% | – | −0.9 pts |
| 1 year | – | +11.2% | – | 11.4% | – | −3.5 pts |
| Since launchNot the same days: PCOV Aug 2026 · TCAL Mar 2025 | −0.1% | +12.0% | 1.9% | 16.9% | not measured | not measured |
– means no data for this window. Open this comparison in the app →
PCOV
Over the period from its first trade on Aug 19, 2026 to Nov 4, 2026, PCOV paid 1.9% of its starting value in cash distributions while its price fell 2.0%. With every distribution reinvested, the fund returned −0.1%. At its price on Nov 4, 2026 the latest distribution annualizes to 7.2%, paid periodically.
TCAL
Over the year to Nov 4, 2026, TCAL paid 11.4% of its starting value in cash distributions while its price fell 1.2%. With every distribution reinvested, the fund returned +11.2%. TCAL's own stocks, without the options (from its filed holdings, rebalanced at each filing; latest Jun 30, 2026) returned +14.6% over the same days, so a holder was behind by 3.4 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 13.0%, paid monthly.
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, PCOV against TCAL, data as of Nov 4, 2026. https://etfiq.com/compare/income/pcov-vs-tcal
ETFIQ. (Nov 4, 2026). PCOV against TCAL. Retrieved from https://etfiq.com/compare/income/pcov-vs-tcal
[PCOV against TCAL (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/pcov-vs-tcal)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.